

NHS Borders
Education Centre
Borders General Hospital
Melrose
Roxburghshire
TD6 9BD
01896 825545
foi.enquiries@borders.scot.nhs.uk



Freedom of Information request 469-20

Request and Response

1. How many patients were diagnosed with prostate cancer over the last 3 months? Of these, how many patients were diagnosed with metastatic prostate cancer?

NHS Borders do not hold diagnosis data electronically therefore to extract this data would require a manual trawl of all patient records and the cost of carrying out this work would exceed the limit set in the Fees Regulations of the FOI(S)A 2002 therefore under Section 12 we are not required to provide.

- 2. How many prostate cancer patients were treated over the last 3 months with:
 - a. Docetaxel 0
 - b. Abiraterone 0
 - c. Enzalutamide 0
 - d. Cabazitaxel <5
- 3. How many patients have been diagnosed with advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer ovarian cancer patients to another trust, if so which one?

NHS Borders do not hold diagnosis data electronically therefore to extract this data would require a manual trawl of all patient records and the cost of carrying out this work would exceed the limit set in the Fees Regulations of the FOI(S)A 2002 therefore under Section 12 we are not required to provide.

4. Of the ovarian cancer patients diagnosed over the last 3 months, how many have been treated with:

Please find below the number of ovarian cancer patients treated with the following over the last 3 months:

a.	Paclitaxel in combination with a platinum-based compound	- <5
b.	Platinum-based therapy alone (cisplatin or carboplatin)	- <5
C.	Bevacizumab in combination with paclitaxel and carboplatin	- 0
d.	Olaparib	- 0
e.	Niraparib	- <5
f.	Rucaparib	- 0

5. Of the ovarian cancer patients diagnosed over the last 3 months, how many have been tested for the BRCA mutation? And of these, how many tested positive?

NHS Borders do not hold diagnosis data electronically therefore to extract this data would require a manual trawl of all patient records and the cost of carrying out this work would exceed the limit set in the Fees Regulations of the FOI(S)A 2002 therefore under Section 12 we are not required to provide.

- 6. Of the ovarian cancer patients who were positive for a BRCA mutation, how many patients received
 - a. Olaparib for 1st line maintenance
 - b. Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance 0

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **469-20** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.